PHM1 N Stock Overview
Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Pharma Mar, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1,608.38 |
| 52 Week High | €0 |
| 52 Week Low | €0 |
| Beta | 0.094 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | 0% |
| 3 Year Change | -8.01% |
| 5 Year Change | n/a |
| Change since IPO | 233.83% |
Recent News & Updates
Recent updates
Shareholder Returns
| PHM1 N | MX Biotechs | MX Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | 0% | 0% | 0% |
Return vs Industry: PHM1 N exceeded the MX Biotechs industry which returned -6% over the past year.
Return vs Market: PHM1 N underperformed the MX Market which returned 3.7% over the past year.
Price Volatility
| PHM1 N volatility | |
|---|---|
| PHM1 N Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: PHM1 N has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine PHM1 N's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | 515 | Jose Maria Fernandez Sousa-Faro | www.pharmamar.com |
Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, France, rest of EU, the United States, and internationally. The company operates through Oncology and RNA interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca for treating patients with small cell lung cancer.
Pharma Mar, S.A. Fundamentals Summary
| PHM1 N fundamental statistics | |
|---|---|
| Market cap | Mex$11.18b |
| Earnings (TTM) | Mex$535.25m |
| Revenue (TTM) | Mex$3.29b |
20.9x
P/E Ratio3.4x
P/S RatioIs PHM1 N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHM1 N income statement (TTM) | |
|---|---|
| Revenue | €177.14m |
| Cost of Revenue | €11.98m |
| Gross Profit | €165.16m |
| Other Expenses | €136.37m |
| Earnings | €28.79m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.59 |
| Gross Margin | 93.24% |
| Net Profit Margin | 16.25% |
| Debt/Equity Ratio | 18.3% |
How did PHM1 N perform over the long term?
See historical performance and comparison